<DOC>
	<DOCNO>NCT02946606</DOCNO>
	<brief_summary>This randomize , active-controlled , open-label , sequential dose group , Phase 1b/2 study design assess safety , tolerability , efficacy , pharmacokinetics , pharmacodynamics weekly every week dose GX-H9 treatment AGHD .</brief_summary>
	<brief_title>A Clinical Study AGHD Assess Safety , Tolerability Efficacy GX-H9</brief_title>
	<detailed_description>The subject adequately eligible attend clinical trial via screen sequentially assign start Group 1 . Each group comprise subject receive GX-H9 Genotropin , subject randomly assign either GX-H9 Genotropin ratio 4:1 . The treatment proceed propose group order ( Group 1 , Group 2 , Group 3 ) , safety insulin-like growth factor ( IGF-1 ) review six week treatment safety monitoring committee proceed next group .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Each subject must meet follow criterion enrol study : 1 . Is male female age ≥20 65 year AGHD , either adult onset GHD due hypothalamic pituitary disease childhood onset GHD either idiopathic due hypothalamic pituitary disease due genetic cause . 2 . Has document confirmation ( medical history ) GH deficiency adulthood 1 growth hormone ( GH ) stimulation test , follow : Insulin tolerance test ( peak hGH≤3.0 ng/mL ) Arginine + growthhormonereleasing hormone ( peak hGH≤4.0 ng/mL ) 3 . Has treat stable hormonal replacement therapy deficiencies hypothalamo pituitary ax must optimize stable treatment regimen least 3 month screen ( free thyroxine [ T4 ] level within normal range screen ) . Temporary adjustment glucocorticoid replacement therapy , appropriate , acceptable . 4 . Has screen IGF1 level least 1 standard deviation ( SD ) score ( IGF1 SD score &lt; 1 ) mean IGF1 level standardize age gender accord central laboratory reference value . 5 . Has BMI ≥18.0 35.0 kg/m2 ( male female subject ) . 6 . Has confirm negative test result antirecombinant human growth hormone ( antirhGH ) antibodies screen . 7 . Must agree use appropriate contraceptive method ( ie , condom , cervical cap conjunction spermicide , sterilization , intra uterine device ) study 6 month last dose study drug . 8 . Female subject must negative serum pregnancy test result screen . 9 . Must willing able provide write informed consent perform study procedure . A subject meeting follow criterion exclude study : 1 . Has evidence growth pituitary adenoma intracranial tumor within last 12 month confirm computed tomography magnetic resonance imaging scan ( contrast ) within 3 month screen . ( Subjects inactive remnant intracranial tumor eligible ) . 2 . Is currently receive antitumor therapy history malignancy ) cranial tumor leukemia cause GHD , ii ) fully treat basal cell carcinoma evidence active malignancy . 3 . Has clinically significant electrocardiogram ( ECG ) abnormality screen . 4 . Has evidence intracranial hypertension screening . 5 . Has uncontrolled diabetes mellitus diet exercise , determine base glycated hemoglobin ( HbA1c ) level ≥7.0 % screening . 6 . Has impair liver function define elevation alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2.0 × upper limit normal ( ULN ) . 7 . Has impair kidney function define increase serum creatinine level great 1.5 × ULN . 8 . Has active acromegaly within 18 month screen . 9 . Has active carpal tunnel syndrome . 10 . Has PraderWilli syndrome . 11 . Has active Cushing syndrome within 12 month screen . 12 . Has major medical condition , include eg , clinically manifest hypertension , tuberculosis , major surgery within 3 month screen , significantly abnormal laboratory test result ( eg , disturbed calcium homeostasis ) ; condition ( eg , acute infection ) may influence drug absorption , metabolism , excretion , may interfere study variable judgment investigator . 13 . Has treat systemic corticosteroid replacement therapy within 3 month screen . 14 . Is female subject childbearing potential pregnant , breastfeeding , intend become pregnant . 15 . Has treat anabolic steroid gonadal steroid replacement therapy within 2 month screen . Oral estrogen replacement hormonal contraceptive allow female subject . For replacement purpose , transdermal estrogen permit female subject . 16 . Has history noncompliance medication , uncooperativeness , alcohol/drug abuse . 17 . Has positive result serology examination hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) . 18 . Has know suspect hypersensitivity rhGH . 19 . Has donate blood major blood loss great 500 mL within 90 day screen . 20 . Has history medical psychiatric condition opinion investigator would pose risk participation study interfere compliance need study . 21 . Has receive investigational drug product participate drug study within 60 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>